Tissue-specific regulatory T cells: Biomarker for acute graft-vs-host disease and survival

Experimental Hematology

Volumn 40, Issue 12, 2012, Pages

  Engelhardt, Brian G ^a   Sengsayadeth, Salyka M ^a   Jagasia, Madan ^a   Savani, Bipin N ^a   Kassim, Adetola A ^a   Lu, Pengcheng ^a   Shyr, Yu ^a   Yoder, Sandra M ^a   Rock, Michael T ^a   Crowe, James E ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CORTICOSTEROID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE HOMING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TISSUE SPECIFICITY; TUMOR ENGRAFTMENT;

EID: 84868707576     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.08.002     Document Type: Article

References (31)

1. Arai S., Vogelsang G.B. Management of graft-versus-host disease. Blood Rev 2000, 14:190-204.
2. Vogelsang G.B., Lee L., Bensen-Kennedy D.M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003, 54:29-52.
3. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 2005, 105:4191-4199.
4. Socie G., Blazar B.R. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009, 114:4327-4336.
5. Yi-Bin C., Kim H.T., McDonough S. Up-regulation of α4β7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1066-1076.
6. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
7. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
8. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
9. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
10. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
11. Hauben E., Bacchetta R., Roncarolo M.G. Utilizing regulatory T cells to control alloreactivity. Cytotherapy 2005, 7:158-165.
12. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
13. Ermann J., Hoffmann P., Edinger M., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
14. Taylor P.A., Panoskaltsis-Mortari A., Swedin J.M., et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104:3804-3812.
15. Cohen J.L., Salomon B.L. Therapeutic potential of CD4+ CD25+ regulatory T cells in allogeneic transplantation. Cytotherapy 2005, 7:166-170.
16. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
17. Nguyen V.H., Zeiser R., Dasilva D.L., et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007, 109:2649-2656.
18. Kim C.H. Migration and function of FoxP3+ regulatory T cells in the hematolymphoid system. Exp Hematol 2006, 34:1033-1040.
19. Engelhardt B.G., Crowe J.E. Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. Curr Top Microbiol Immunol 2010, 341:121-146.
20. Campbell D.J., Koch M.A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011, 11:119-130.
21. Engelhardt B.G., Jagasia M., Savani B.N., et al. Regulatory T cell expression of CLA or alpha(4)beta(7) and skin or gut acute GVHD outcomes. Bone Marrow Transplant 2010, 46:436-442.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25:195-201.
24. Rieger K., Loddenkemper C., Maul J., et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006, 107:1717-1723.
25. Fondi C., Nozzoli C., Benemei S., et al. Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant 2009, 15:938-947.
26. Zhang N., Schroppel B., Lal G., et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009, 30:458-469.
27. Lord J.D., Hackman R.C., Gooley T.A., et al. Blood and gastric FOXP3(+) T cells are not decreased in human gastric graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:486-496.
28. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
29. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:320-327.
30. Chao N.J., Schmidt G.M., Niland J.C., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993, 329:1225-1230.
31. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.